Skip to main content
Two-year dupilumab data: Continued response for moderate to severe pediatric asthma
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Two-year dupilumab data: Continued response for moderate to severe pediatric asthma
User login
Username
Password
Reset your password
Concept
Lead
score
Severe Asthma
1
1
Child
0
0.99
Otolaryngology
0
0.95
Asthma
0
0.81
Steroids
0
0.61
Biologic Therapy
0
0.98
Patient Safety
0
0.15
Adverse Effects
0
0.14
Bone
0
0.14
Eosinophils
0
0.09
Lung
0
0.09
Inhaled Corticosteroid
0
0.07
Upper Respiratory Tract Infection
0
0.07
Allergy
0
0.05
Cancer
0
0.05
Corticosteroids
0
0.05
Diarrhea
0
0.05
Eosinophilia
0
0.05
Immunology
0
0.05
Influenza
0
0.05
Nasopharyngitis
0
0.05
Pharyngitis
0
0.05
Respiratory Tract
0
0.05
Rhinitis
0
0.05
Thorax
0
0.05
Specialty
Lead
score
Pulmonary Medicine
1
1
Family Medicine/Primary Care
0
0.9
Pediatrics
0
0.8
Edit Tags